Binding molecules directed against influenza hemagglutinin and uses thereof

Patent metadata

Field	Value
Publication number	US-10370435-B2
Application number	US-201615548843-A
Country	US
Kind code	B2
Filing date	Feb 5, 2016
Priority date	Feb 5, 2015
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.

First claim

The invention claimed is:

1. A multi-domain antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 303 and SEQ ID NO:305.

2. The multi-domain antibody according to claim 1 , comprising the amino acid sequence of SEQ ID NO:303 and the amino acid sequence of SEQ ID NO:305.

3. A multi-domain antibody comprising a first polypeptide comprising two single domain antibodies fused together via a linker, wherein the two single domain antibodies comprise the amino acid sequences of SEQ ID NOs: 155, and 176, respectively.

4. The multi-domain antibody according to claim 3 , further comprising a second polypeptide comprising two single domain antibodies fused together via a linker, wherein the two single domain antibodies comprise the amino acid sequences of SEQ ID NOs: 221 and 203, respectively.

5. The multi-domain antibody according to claim 3 , further comprising a human Fc tail.

6. A pharmaceutical composition comprising the multi-domain antibody according to claim 1 .

7. A pharmaceutical composition comprising the multi-domain antibody according to claim 3 .

8. A nucleic acid molecule encoding the multi-domain antibody according to claim 1 .

9. A nucleic acid molecule encoding the multi-domain antibody according to claim 3 .

Assignees

• Janssen Vaccines & Prevention Bv

Inventors

• Brandenburg Boerries
• Vogels Ronald
• Kolkman Joost A
• Friesen Robert Heinz Edward

Classifications

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C07K16/108 Primary

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• C07K2317/22

  from camelids, e.g. camel, llama or dromedary · CPC title

• A61K2039/543

  intranasal · CPC title

• A61K2039/505

  comprising antibodies · CPC title